Placebo-Controlled Discontinuation of Long-Term Acid-Suppressant Therapy: A Randomised Trial in General Practice

Table 3

Associations with discontinuation in placebo group ().

	Successful discontinuation; (continuing placebo); ()	Unsuccessful discontinuation; (discontinuing placebo); ()	value
Age median (IQR), year	58 (48–62)	60 (51–69)	0.81
Male (%)	23%	58%	0.003
Helicobacter pylori-positive, % (95% CI)	29 (12–51)	17 (8–29)	0.24
No nicotine use, % (95% CI)	68 (46–85)	50 (37–63)	0.12
Alcohol use, <21 units/weeks, % (95% CI)	92 (74–99)	92 (82–97)	0.96
Symptom duration, median (10%; 90%) percentile, year	4 (0–13)	4 (1–14)	0.21
Previous endoscopy, % (95% CI)	40 (21–61)	47 (24–60)	0.58
Previous NSAID/ASA use, % (95% CI)	60 (39–79)	62 (48–74)	0.89
GSRS total, mean (95% CI)	2.5 (2.2–2.8)	2.9 (2.5–3.2)	0.07
GSRS reflux score, mean (95% CI)	3.0 (2.5–3.5)	3.3 (2.9–3.8)	0.29
SF-36 physical health summary score, mean score (95% CI)	41 (36–46)	43 (40–46)	0.54
SF-36 mental health summary score, mean score (95% CI)	48 (42–54)	51 (49–54)	0.20

-test for linear regression.